Kornimate/medical-research-clean huggingface dataset:
combination of cisplatin plus gemcitabine induction chemotherapy and intensity-modulated radiotherapyintensity-modulated radiotherapy with or without concurrent cisplatin for npc

Conditions: Nasopharyngeal Carcinoma

Summary: concurrent cisplatin-based chemotherapy plus radiotherapy increased the risk of treatment-related death and severe acute toxicity. the survival benefit of adding concurrent chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma is unclear. gemcitabine plus cisplatin chemotherapy combine with radiotherapy was effective and well tolerated by patients with locoregionally advanced npc.

the purpose of this study is to compare gemcitabine plus cisplatin induction chemotherapy combine intensity-modulated radiotherapy with or without concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma (npc), in order to reevaluate the value of concurrent cisplatin when 4 cycles induction chemotherapy (gemcitabine+cisplatin) and imrt is used.

Eligibility criteria:
inclusion criteria: * patients with newly histologically confirmed non-keratinizing (according to world health organization (who 2005) histologically type). * a karnofsky performance status of at least 80; * tumor staged is according to the 7th american joint commission on cancer edition as stage iii：t1-2n2m0, t3n0-2m0 stage iva：t4n0-2m0 stage ivb：any t、n3. * adequate marrow: a wbc ≥3.5×109 l-1; a platelet count ≥100×109 l-1; and hemoglobin levels ≥100 g/l. * normal liver function test: alanine aminotransferase (alt)、aspartate aminotransferase (ast) \<1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤2.5×uln, and bilirubin ≤uln. * adequate renal function: a creatinine clearance rate of at least 60 ml/min. * patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: * who type keratinizing squamous cell carcinoma. * age \>65 years or \<18 years. * distant metastasis, * treatment with palliative intent. * pregnancy or lactation. * a history of previous radiotherapy in the nasopharyngeal region or previous chemotherapy. * history of renal disease, unstable cardiac disease requiring treatment.

Keywords: cisplatin neoadjuvant chemotherapy intensity-modulated radiation therapy concurrent chemoradiotherapy
a controlled trial of protein enrichment of meal replacements for weight reduction with retention of lean body mass

Conditions: Weight Loss; Obesity

Summary: study hypothesis: high protein diets have been shown to make people full and and help to retent of muscle mass. this study was designed to determine effects of a protein- enriched meal replacement (mr) on weight loss and muscle mass retention by comparison to an equal calorie carbohydrate-enriched mr. methods: single blind, placebo-controlled, randomized outpatient weight loss trial in 100 obese men and women comparing two equal calorie meal plans.,1) 2.2 g protein/kg of lbm per day \[high protein diet (hp)\] or 2) 1.1 g protein/kg lbm/day standard protein diet (sp). body weight, body composition, and lipid profiles were measured at baseline and 12 weeks.

background: while high protein diets have been shown to improve satiety and retention of lean body mass (lbm), this study was designed to determine effects of a protein- enriched meal replacement (mr) on weight loss and lbm retention by comparison to an isocaloric carbohydrate-enriched mr within customized diet plans utilizing mr to achieve high protein or standard protein intakes. methods: single blind, placebo-controlled, randomized outpatient weight loss trial in 100 obese men and women comparing two isocaloric meal plans utilizing a standard mr to which was added supplementary protein or carbohydrate powder. mr were used twice daily (one meal, one snack). one additional meal was included in the meal plan designed to achieve individualized protein intakes of either 1) 2.2 g protein/kg of lbm per day \[high protein diet (hp)\] or 2) 1.1 g protein/kg lbm/day standard protein diet (sp). lbm was determined using bioelectrical impedance analysis (bia). body weight, body composition, and lipid profiles were measured at baseline and 12 weeks.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 27 to 40 kg/m2 * in good health by history, physical examination, and basic laboratory screening (complete blood count, serum chemistries, liver panel, and lipid panel) exclusion criteria: * type 2 diabetes or glucose intolerance * regularly drank more than one alcoholic beverage daily * unable to provide consent

Keywords: weight loss obesity high protein meal replacement
endometriosis of the recto-sigmoid: mri (magnetic resonance imaging) criteria predictive of shaving or segmental resection

Conditions: Endometriotic Parietal Involvement of the Rectosigmoid

Summary: evaluate mri criteria predictive of the type of surgery to be performed for an "in sano" resection of endometriotic involvement of the recto-sigmoid by a resection without opening of the rectal mucosa ("shaving") versus a segmental resection.

purpose: to retrospectively determine the accuracy of mri rectal and pararectal signs in predicting a segmental resection of lesions located in the rectum until the recto-sigmoid junction. materials and methods: institutional review board approval for this study was obtained and waived written informed consent. the mr images of 61 patients treated for rectal endometriosis over a 6 years period were reviewed. two blinded readers performed in consensus a systematic analysis of 7 rectal (length, transverse axis, thickness and circumference of the lesion, and presence of a convex base, submucosal edema and hyperintense cystic areas) and 4 pararectal (posterior vaginal fornix, parametrial, ureteral and sacro-recto-genital septum involvements) signs for each lesion. mr imaging results were compared with surgical procedure (shaving versus segmental resection). efficacy parameters were calculated with 95 % confidence intervals (cis).

Eligibility criteria:
inclusion criteria: * operated patient for a pelvic endometriosis with resection without opening of the rectal mucosa ("shaving") or with segmental resection of the recto-sigmoidienne. * performing a preoperative pelvic mri with at least 2 perpendicular t2 planes exclusion criteria: * refusal to use clinical data and exploration acquired * absence of interpretable preoperative pelvic mri
evaluation of a full face mask for the treatment of obstructive sleep apnea (osa) in nz

Conditions: Obstructive Sleep Apnea

Summary: this investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the investigative full face mask amongst osa participants.

a total number of up to 15 osa participants who currently use full face masks will be recruited for the trial. participants will be on the trial for three weeks, using the prototypes at home for two weeks. pap baseline data on the participant's prescribed treatment pressure with their usual mask and will be collected for one week prior to mask fitting with the full face trial mask.

Eligibility criteria:
inclusion criteria: * 18+ years of age * diagnosed with osa by a practicing physician * prescribed pap therapy (bi-level or continuous positive airway pressure (cpap) or automatic positive airway pressure (apap)) * existing full face users exclusion criteria: * inability to give informed consent * patients who are in a coma or decreased level of consciousness * anatomical or physiological conditions making pap therapy inappropriate (e.g unconsolidated facial fracture) * commercial drivers who are investigated by new zealand transport agency (nzta) * current diagnosis of co2 retention * pregnant or think they may be pregnant
effectiveness of ketamine treatment for three consecutive days in depression

Conditions: Depression

Summary: inclusion criteria: 1. patient over 20 years old with depression diagnosed by a psychiatrist and madrs \>= 25 scores; 2. failed to improve by at least optimal dosage of two antidepressants for four weeks and one psychotherapy. patients and outcome assessors will be blinded from intervention the patients have. participants will be randomized into two groups that are intervention (ketamine 0.5 mg/kg iv drip in 40 minutes) and control (midazolam 0.045 mg/kg iv drip in 40 minutes) groups. participants will administer ketamine/midazolam once daily for three consecutive days. they will be evaluate madrs changing, vital signs, dissociative symptoms, cgi, and quality of life (eq-5d-5l) during the treatment, at 1 week and 4 weeks after treatment completion.


Eligibility criteria:
inclusion criteria: * over 20 years old * depression was diagnosed by a psychiatrist and having madrs \>= 25 * depression treated with 2 optimal dosage of antidepressants for 4 weeks and one psychotherapy * stable dosage of current medications for 4 weeks * fluently thai exclusion criteria: * secondary depression * ptsd * current pregnancy * history of increased intracranial hemorrhage, increased intracranial pressure, severe head injury, abnormal thyroid function, angina, heart failure, arrhythmia, aneurysm, uncontrolled hypertension, chronic lower tract respiratory disease, myasthenia gravis, glaucoma, dementia, acute porphyria, or cystitic (within 3 months prior to recruitment) * allergy to ketamine or midazolam * history of substance use disorder within 1 year prior to recruitment * history of psychosis within 3 months * history of bipolar disorder * bmi over 35 * frail medical condition * currently ect or tms
neonatal intensive care unit (nicu) diaper dermatitis: prevention and treatment with airtime

Conditions: Diaper Dermatitis

Summary: the purpose of this study is to investigate the use of 3-5 minutes air therapy for the prevention and treatment of diaper dermatitis in infants 30 weeks and older receiving care in the neonatal intensive care unit (nicu).


Eligibility criteria:
inclusion criteria: * receiving care at good samaritan hospital nicu * at least 30 weeks gestation at birth and corrected or older or corrected gestation * birth to 1 year old * stable vital signs (temperature, pulse, blood pressure, and oxygen saturation) exclusion criteria: * parent/legal guardian unable or unavailable to consent to involvement in the study * congenital malformation impacting diaper area or spine
multimodal assessment of neurobiological markers for psychiatric disorders

Conditions: Major Depressive Disorder (MDD); Anxiety Disorder

Summary: man-biopsy pursues the concrete research question whether novel biological and psycho-physiological clusters or categories can be defined to improve treatment and minimize side effects in psychiatry, based on a synopsis of physiological, behavioural, genetic and endocrinological parameters. one major aspect of our research approach is its focuses on the identification of dysfunctions in fundamental information processing mechanisms and neurocomputational mechanisms, and is not restricted to symptom-oriented tasks. the main objectives of man-biopsy are therefore * to identify biological and psycho-physiological parameters for major depressive disorders and anxiety disorders, and * to identify predictive markers for treatment response and type/severity of side effects for these disorders.


Eligibility criteria:
inclusion criteria for patients: * dsm-iv-tr diagnosis of mdd or an anxiety disorder (excluding ptsd, specific phobias, and bipolar disorder) by a structured clinical interview (scid) * aged 18 to 50 years * drug-free within the last three months prior inclusion * willingness and competence to sign the informed consent form inclusion criteria for remitted subjects: * a previous dsm-iv-tr diagnosis of mdd or an anxiety disorder (excluding ptsd, specific phobias, and bipolar disorder) but no symptoms at present, determined by scid * aged 18-50 years * drug-free within the last three months prior inclusion * willingness and competence to sign the informed consent form inclusion criteria for healthy control subjects: * inclusion criteria for healthy control subjects are * willingness and competence to sign the informed consent form * aged 18-50 years * drug-free exclusion criteria: * concomitant major internal or neurological illness * concomitant psychiatric disorders (except depression and anxiety for patients, excluding ptsd, claustrophobia and bipolar disorder) * ingestion of any antipsychotic, antidepressant, or anti-anxiety agent within the last three months prior to the screening visit * current substance abuse * failure to comply with the study protocol or to follow the instructions of the investigating team
epidemiological study of colorectal cancer in wuhan

Conditions: Diarrhea; Constipation; Melena; Neoplasm; Colonic Neoplasms; Pain

Summary: the incidence risk of colorectal cancer （crc） is increasing at 4.2% year by year in china. most effective way to reduce the death rate of crc patients is to diagnose in quite an early stage. qiaokou district is a chemical industry zone of wuhan with a long history, which has few data of crc epidemiology. the investigators design the primary crc screening for this district by healthy questionnaire, fecal occult blood test(fobt) and colonoscopy. hanyang areo has been chosen as control for its non-industry environment.the crowd would be screen biennially. the high risk group would be intervened, such as resection of polyps or other specific treatment. a follow-up registration database has been built for analysis the relationship between incidence or death rate to high risk factors, such as age, life environment, lifestyles, base diseases and family history of cancer. this study will provide some epidemiology dates of crc to the local government, and assist the governor to built a more effective screening system of crc.

for this study, you will be asked to complete a personal interview. during the interview, you will be asked questions about your demographics (age, sex, etc.), underlying diseases, lifestyle, family history of cancer, awareness of crc. it should take around 30 minutes to complete the interview. residents in high risk group need to have some special tests, including fobt and colonoscopy. intestinal neoplasm will be suggested to biopsy or remove under colonoscopy for pathological examination. all tests are free. the interviews will be performed in residential area and special tests will be done in the hospital during a regularly scheduled visit to pu-ai hospita.you may be contacted at home by phone so that researchers can collect information about any changes in your health status.

Eligibility criteria:
inclusion criteria: 1. aged 40-74 2. resident of qiaokou areo，and at least ten years living history in this district 3. willing and able to provide written informed consent and authorization 4. willing to a personal interview and have some special tests exclusion criteria: 1. under 43 or older than 74 years of age 2. history of colorectal cancer 3. mental disorders

Keywords: colorectal cancer epidemiology industry genetic
cetuximab rechallenge in irinotecan-pretreated mcrc, kras, nras and braf wild-type treated in 1st line with anti-egfr therapy (cricket).

Conditions: Metastatic Colorectal Cancer

Summary: this is a multicentric, phase ii single-arm study in which kras, nras and braf wild-type, irinotecan-resistant metastatic colorectal cancer patients progressing after an initial response to a first-line cetuximab-containing therapy, receive a rechallenge third-line treatment with cetuximab plus irinotecan.


Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of colorectal adenocarcinoma; * ras and braf wild-type status; * first-line irinotecan-based (folfiri or folfoxiri) cetuximab-containing therapy producing at least a partial response; * first-line progression-free survival in response to cetuximab-containing therapy ≥6 months; * documentation of progression to first-line cetuximab within 4 weeks after last cetuximab administration; * time between the end of first-line therapy and the start of third-line treatment with cetuximab plus irinotecan ≥4 months; * second-line oxaliplatin-based (folfoxiri, folfox or xelox) bevacizumab-containing therapy; * documentation of progression to second-line treatment; * measurable disease according to recist criteria v1.1; * have tumor tissue (of primary tumor and metastases or at least one of the two) available for biomarker analysis; * male or female patients \> 18 years of age; * ecog performance status ≤ 2; * life expectancy of at least 3 months; * adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment; * women of childbearing potential must have a negative blood pregnancy test at the baseline visit. for this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile or are sexually inactive; * subjects and their partners must be willing to avoid pregnancy during the trial and until 6 months after the last trial treatment. male subjects with female partners of childbearing potential and female subjects of childbearing potential must, therefore, be willing to use adequate contraception as approved by the investigator, such as a two-barrier method or one-barrier method with spermicidal or intrauterine device. this requirement begins 2 weeks before receiving the first trial treatment and ends 6 months after receiving the last treatment; * signed informed consent obtained before any study specific procedure. exclusion criteria: * active uncontrolled infections or active disseminated intravascular coagulation; * past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix; * fertile women (\< 12 months after last menstruation) and men of childbearing potential not willing to use effective means of contraception * women who are pregnant or are breastfeeding; * previous grade 3/4 infusion related reaction to cetuximab.

Keywords: cetuximab rechallenge
facial cosmetic acupuncture on skin rejuvenation

Conditions: Skin Aging; Skin Wrinklings

Summary: facial cosmetic acupuncture technique includes wrinkles, acupoints and muscle points on the face, head and neck. this study is designed to determine the efficacy and safety of facial cosmetic acupuncture on skin rejuvenation.


Eligibility criteria:
inclusion criteria: * patient age of 40 to 59 years * glogau photoaging scale iii-iv exclusion criteria: * who had undergone any dermabrasion, deep skin peels, laser resurfacing (ablative or non-ablative), botulinum toxin or filler injection, topical steroid within 6 months prior to study entry * patient with obvious skin disease * patient with a history of chronic skin disease * keloidal or hypertrophic scar tendency * pregnant or lactating patients

Keywords: facial cosmetic acupuncture skin rejuvenation skin aging
povidone iodine and cesarean section wound infections

Conditions: Wound Infections

Summary: the aim of this randomized clinical trial is to compare the efficiency of hand scrubbing by povidone-iodine solution 10% over 7.5% concentration in decreasing post-cesarean section wound infections \& compare side effects of both agents.

for centuries, hand washing with soap and water has been considered the main approach for personal hygiene. in the community, hand hygiene has been known to prevent infectious diseases and to decrease the burden of disease. currently, hand hygiene is considered the most important measure for preventing the spread of pathogens in health-care settings. there are multiple agents used for surgical hand scrubbing as alcohol, chlorhexidine, iodine/iodophors, para-chloro-meta-xylenol \& triclosan. ideally, the optimum antiseptic used for scrub should have broad spectrum of activity, persistent effect \& fast acting. unfortunately most studies evaluating surgical scrub antiseptics have focused on measuring hand bacterial colony counts. no randomized clinical trials have evaluated the impact of surgical scrub choice on surgical site infection risk \& proven its efficiency.

Eligibility criteria:
inclusion criteria: * elective caesarian section (cs) exclusion criteria: * diabetes, * immuno-compromised patients

Keywords: betadine povidine iodine hand scrubbing cesarean section wound infections post cesarean section
determination of the utility of pfizer's pneumococcal urine antigen test in children 5 years of age or younger with community acquired pneumonia in guatemala

Conditions: Community-acquired Pneumonia; Streptococcus Pneumoniae Infection

Summary: this prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of age or younger in guatemala.


Eligibility criteria:
cases: inclusion criteria: * age older than 1 month (31 days) and up to 71 months and 28 days. * diagnosis of radiologically confirmed pneumonia per who criteria in the ed or hospital within 48 hours of hospital admission * signed informed consent by parents or legal guardian to participate in the study exclusion criteria: * known immunodeficiency * major congenital malformation (e.g., hemodynamically compromised congenital heart malformation or any malformation leading to recurrent pneumonia) or serious chronic disorder * significant neurological disorder * hospitalization within the previous 30 days for pneumonia or respiratory infection * use of parenteral antibiotics for current illness (leading to diagnosis of pneumonia) * transferred to the study hospital after already being hospitalized at a different location for ≥ 48 hours controls: inclusion criteria: * age 1 to 71 months and signed informed consent by parents or legal guardian exclusion criteria: * known immunodeficiency * major congenital malformation (e.g., hemodynamically compromised congenital heart malformation or any malformation leading to recurrent pneumonia) or serious chronic disorder * significant neurological disorder * fever or suspicion of community-acquired pneumonia or other respiratory infectious disease (symptoms of cough, congestion, tachypnea, indrawing, etc.) * hospitalization within the previous 30 days for pneumonia or respiratory infection

Keywords: streptococcus pneumoniae pneumonia community-acquired pediatric urine antigen
stratification for f-l therapy after lt

Conditions: Liver Transplantation; Adjuvant FOLFOX Plus Lenvatinib; Machine Learning

Summary: objective: to stratify recipients who underwent adjuvant folfox plus lenvatinib (f-l) therapy following liver transplantation (lt) for hepatocellular carcinoma and provide guidance for clinical adjuvant therapy. methods: liver recipients in the shulan (hangzhou) hospital from january, 2017 to december, 2021, including 106 in the f-l therapy group and 229 in the non-adjuvant (n-a) therapy group were included in the analysis. a 1:1 propensity score matching (psm) analysis was performed to minimize group imbalances. disease-free survival (dfs) and overall survival (os) were compared among recipients. radiomics features that demonstrated predictive value for recurrence were employed, either independently or in conjunction with prognostic clinical features, to formulate predictive models. the combined model was used to perform further subgroup analysis for recipients in the f-l therapy group.


Eligibility criteria:
inclusion criteria: * patients fulfilling the hangzhou criteria or exceeding the hangzhou criteria with type 1 or 2 portal vein tumor thrombus (pvtt) before lt exclusion criteria: * 1) individuals less than 18 years old; 2) individuals with malignancies other than hcc; 3) individuals who survived less than 30 days after lt; and 4) individuals who lacked important prognostic variables, such as contrast-enhanced ct imaging information one month before transplantation, preoperative alpha-fetoprotein (afp) levels, and tumor differentiation data